Drug
Dactolisib clinical trials
Also written BEZ235 and RTB101.
- studies test it
- 24
- open now
- 0
- in phase 3
- 2
- first study started
- 2006
How studies write it
Studies that test it under each name
Name
Combined with it in one product
Studies by the year they started
24 studies that test it; most in 2012 (10)
| Year | Studies |
|---|---|
| 2006 | 1 |
| 2010 | 2 |
| 2011 | 4 |
| 2012 | 10 |
| 2013 | 2 |
| 2017 | 1 |
| 2019 | 2 |
| 2020 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 13
- Phase 2
- 12
- Phase 3
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 17 · Other 7
Novartis Pharmaceuticals (11) · Restorbio Inc. (5) · Goethe University (1) · Pfizer (1) · Vanderbilt-Ingram Cancer Center (1) · SCRI Development Innovations, LLC (1) · Cliniques universitaires Saint-Luc- Université Catholique de Louvain (1) · Charles Ryan (1)
Often tested with
Tested in the same studies.
Everolimus (3) · Buparlisib (3) · Paclitaxel (2) · Trastuzumab (1) · Binimetinib (1) · Abiraterone Acetate (1) · Abiraterone (1)
Studies
Open first, then newest update. How each study uses dactolisib is read from its arms, and is right about nine times in ten.
Testing it · 24
- A Phase I, Dose-finding Study of BEZ235 in Adult Patients With Relapsed or Refractory Acute LeukemiaCompletedPhase 1Goethe UniversityNCT01756118Written as BEZ235
- A Phase 3 Study to Determine if RTB101 Prevents Clinically Symptomatic Respiratory Illness in the ElderlyCompletedPhase 3Restorbio Inc.NCT04668352Written as Dactolisib
- Phase 2 Study to Determine if RTB101 Reduces the Severity of COVID-19 in Older Adults Residing in Nursing HomesTerminatedPhase 2Restorbio Inc.NCT04409327Written as RTB101
- A Phase 2 Study of RTB101 as COVID-19 Post-Exposure Prophylaxis in Older AdultsActive, not recruitingPhase 2Restorbio Inc.NCT04584710Written as RTB101
- Dose Finding Study of RAD001 (Everolimus, Afinitor®) in Combination With BEZ235 in Patients With Advanced Solid TumorsCompletedPhase 1Novartis PharmaceuticalsNCT01482156Written as RAD001 + BEZ235
- A Study of BEZ235 in Adult Japanese Patients With Advanced Solid TumorsCompletedPhase 1Novartis PharmaceuticalsNCT01195376Written as BEZ235
- A Trial of Oral BEZ235 and BKM120 in Combination With Paclitaxel With or Without TrastuzumabCompletedPhase 1Novartis PharmaceuticalsNCT01285466Written as BEZ235 + paclitaxel
- A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast CancerCompletedPhase 1Novartis PharmaceuticalsNCT00620594Written as BEZ235
- Phase Ib of Abiraterone Acetate Plus BEZ235 or BKM120 in Castration-resistant Prostate Cancer (CRPC) PatientsCompletedPhase 1Novartis PharmaceuticalsNCT01634061Written as BEZ235
- Phase Ib/II Trial of BEZ235 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast CancerTerminatedPhase 1/2Novartis PharmaceuticalsNCT01495247Written as BEZ235
- Safety, Pharmacokinetics and Pharmacodynamics of BEZ235 Plus MEK162 in Selected Advanced Solid Tumor PatientsCompletedPhase 1PfizerNCT01337765Written as BEZ235 + MEK162
- Effect of RTB101 on Illness Associated With Respiratory Tract Infections in the ElderlyWithdrawnPhase 3Restorbio Inc.NCT04139915Written as Dactolisib
- Study of BEZ235 as Monotherapy in Patients With Transitional Cell Carcinoma After Failure of Platinum Based ChemotherapyTerminatedPhase 2Cliniques universitaires Saint-Luc- Université Catholique de LouvainNCT01856101Written as BEZ235
- Dose Finding Study to Determine if BEZ235 Alone or in Combination With RAD001 Decreases the Incidence of Respiratory Tract Infections in the ElderlyActive, not recruitingPhase 2Restorbio Inc.NCT03373903Written as BEZ235
- A Multicenter Phase I/II Trial of Abiraterone Acetate + BEZ235 in Metastatic, Castration-Resistant Prostate CancerTerminatedPhase 1/2Charles RyanNCT01717898Written as BEZ235
- Safety Study of BEZ235 With Everolimus in Subjects With Advanced Solid TumorsTerminatedPhase 1University of CincinnatiNCT01508104Written as BEZ235
- PhIb BKM120 or BEZ235+Endocrine Treatment in Post-Menopausal Patients With Hormone Receptor + Metastatic Breast CancerCompletedPhase 1Vanderbilt-Ingram Cancer CenterNCT01248494Written as BEZ235
- BEZ235 Phase II Trial in Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET) After Failure of mTOR Inhibitor Therapy.CompletedPhase 2Novartis PharmaceuticalsNCT01658436Written as BEZ235 (Stage 1)
- Efficacy and Safety of BEZ235 Compared to Everolimus in Patients With Advanced Pancreatic Neuroendocrine TumorsTerminatedPhase 2Novartis PharmaceuticalsNCT01628913Written as BEZ235
- BEZ235 in Patients With Advanced Renal Cell Carcinoma (RCC)TerminatedPhase 1/2Memorial Sloan Kettering Cancer CenterNCT01453595Written as BEZ235
Codes
What other systems call dactolisib · ClinicalTrials.gg INT005316
- MeSH (NLM) C531198dactolisibConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) RUJ6Z9Y0DTDACTOLISIBConfirmed FDA, NLM, Wikidata
- Wikidata Q4835503dactolisibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C74072DactolisibOne source FDA
- DrugBank DB11651One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C531198 | dactolisib | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | RUJ6Z9Y0DT | DACTOLISIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q4835503 | dactolisib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C74072 | Dactolisib | One source FDA |
| DrugBank | DB11651 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.